

Katarina Sjögren Gleisner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/318048/publications.pdf>

Version: 2024-02-01

39
papers

1,373
citations

331670

21
h-index

330143

37
g-index

39
all docs

39
docs citations

39
times ranked

955
citing authors

#	ARTICLE	IF	CITATIONS
1	Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with ¹⁷⁷ Lu-DOTATATE. Journal of Nuclear Medicine, 2022, 63, 399-405.	5.0	30
2	EANM dosimetry committee recommendations for dosimetry of ¹⁷⁷ Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1778-1809.	6.4	70
3	Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based ¹⁷⁷ Lu-DOTATATE treatment of NET patients. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3830-3840.	6.4	30
4	Monte Carlo modelling of a compact CZT-based gamma camera with application to ¹⁷⁷ Lu imaging. EJNMMI Physics, 2022, 9, 35.	2.7	1
5	A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project. EJNMMI Physics, 2021, 8, 55.	2.7	34
6	Characterisation of a hand-held CZT-based gamma camera for ¹⁷⁷ Lu imaging. EJNMMI Physics, 2020, 7, 46.	2.7	7
7	Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11â€“GBq and 3.7â€“GBq of ¹³¹ I-Nal respectively. Physica Medica, 2019, 65, 143-149.	0.7	8
8	Bone Marrow Absorbed Doses and Correlations with Hematologic Response During ¹⁷⁷ Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. Journal of Nuclear Medicine, 2019, 60, 1406-1413.	5.0	41
9	Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2019, 30, 2047-2048.	0.5	3
10	From fixed activities to personalized treatments in radionuclide therapy: lost in translation?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 152-154.	6.4	34
11	Feasibility of simplifying renal dosimetry in ¹⁷⁷ Lu peptide receptor radionuclide therapy. EJNMMI Physics, 2018, 5, 12.	2.7	60
12	EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2456-2474.	6.4	124
13	3-D Image-Based Dosimetry in Radionuclide Therapy. IEEE Transactions on Radiation and Plasma Medical Sciences, 2018, 2, 527-540.	3.7	21
14	A method for tumor dosimetry based on hybrid planarâ€“SPECT/CT images and semiautomatic segmentation. Medical Physics, 2018, 45, 5004-5018.	3.0	16
15	SPECT image segmentation for estimation of tumour volume and activity concentration in ¹⁷⁷ Lu-DOTATATE radionuclide therapy. EJNMMI Research, 2017, 7, 18.	2.5	26
16	Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. Journal of Nuclear Medicine, 2017, 58, 862-862.	5.0	8
17	The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1783-1786.	6.4	48
18	Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. EJNMMI Physics, 2017, 4, 28.	2.7	65

#	ARTICLE	IF	CITATIONS
19	Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. <i>EJNMMI Physics</i> , 2017, 4, 27.	2.7	71
20	Personalized Dosimetry for Radionuclide Therapy Using Molecular Imaging Tools. <i>Biomedicines</i> , 2016, 4, 25.	3.2	22
21	Biologically effective dose in fractionated molecular radiotherapy—application to treatment of neuroblastoma with ¹³¹ I-MIBG. <i>Physics in Medicine and Biology</i> , 2016, 61, 2532-2551.	3.0	9
22	Whole-body remnant and maximum voxel SPECT/CT dosimetry in ¹³¹ I renal treatments of differentiated thyroid cancer. <i>Medical Physics</i> , 2016, 43, 5279-5287.	3.0	19
23	Hybrid Imaging for Patient-Specific Dosimetry in Radionuclide Therapy. <i>Diagnostics</i> , 2015, 5, 296-317.	2.6	19
24	Pharmacokinetic digital phantoms for accuracy assessment of image-based dosimetry in ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy. <i>Physics in Medicine and Biology</i> , 2015, 60, 6131-6149.	3.0	32
25	Long-Term Retention of ¹⁷⁷ Lu/ ^{177m} Lu-DOTATATE in Patients Investigated by ¹³¹ I-Spectrometry and ¹³¹ I-Camera Imaging. <i>Journal of Nuclear Medicine</i> , 2015, 56, 976-984.	5.0	27
26	Uncertainty propagation for SPECT/CT-based renal dosimetry in ¹⁷⁷ Lu peptide receptor radionuclide therapy. <i>Physics in Medicine and Biology</i> , 2015, 60, 8329-8346.	3.0	45
27	Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with ¹³¹ I-metaiodobenzylguanidine with implications for the activity to administer. <i>Medical Physics</i> , 2015, 42, 3969-3978.	3.0	15
28	The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1976-1988.	6.4	179
29	On the biologically effective dose (BED) using convolution for calculating the effects of repair: II. Numerical considerations. <i>Physics in Medicine and Biology</i> , 2013, 58, 1529-1548.	3.0	20
30	On the biologically effective dose (BED) using convolution for calculating the effects of repair: I. Analytical considerations. <i>Physics in Medicine and Biology</i> , 2013, 58, 1507-1527.	3.0	18
31	Dynamic ^{99m} Tc-MAG3 renography: images for quality control obtained by combining pharmacokinetic modelling, an anthropomorphic computer phantom and Monte Carlo simulated scintillation camera imaging. <i>Physics in Medicine and Biology</i> , 2013, 58, 3145-3161.	3.0	14
32	Radionuclide Metabolic Therapy. , 2013, , .		0
33	Patient-Specific Whole-Body Attenuation Correction Maps from a CT System for Conjugate-View-Based Activity Quantification: Method Development and Evaluation. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 652-664.	1.0	11
34	Evaluation of quantitative planar ⁹⁰ Y bremsstrahlung whole-body imaging. <i>Physics in Medicine and Biology</i> , 2009, 54, 5873-5883.	3.0	45
35	High-Dose Iodine-131-Metaiodobenzylguanidine with Haploidentical Stem Cell Transplantation and Posttransplant Immunotherapy in Children with Relapsed/Refractory Neuroblastoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1077-1085.	2.0	39
36	Development and Evaluation of a Pharmacokinetic Model for Prediction of Radioimmunotherapy Based on Pretherapy Data. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 111-122.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Evaluation of quantitative ⁹⁰ Y SPECT based on experimental phantom studies. Physics in Medicine and Biology, 2008, 53, 5689-5703.	3.0	120
38	Consequences of inadvertent radioiodine treatment of Gravesâ€™ disease and thyroid cancer in undiagnosed pregnancy. Can we rely on routine pregnancy testing?. Acta OncolÃ³gica, 2008, 47, 145-149.	1.8	28
39	Parametric Images of Antibody Pharmacokinetics Based on Serial Quantitative Whole-Body Imaging and Blood Sampling. Journal of Nuclear Medicine, 2007, 48, 1369-1378.	5.0	7